



**KINEXUS**

## **Kinexus receives Eligible Business Corporation (EBC) Status**

*Kinexus investors can receive a 30% refundable tax credit*

**FOR IMMEDIATE RELEASE SEPTEMBER 19, 2003**

**VANCOUVER, British Columbia** – Kinexus Bioinformatics Corporation, a Canadian proteomics company, is pleased to announce it has received Eligible Business Corporation (EBC) Status under section 28.2 of the *Small Business Venture Capital Act*. The EBC status is a new investment option designed to promote capital investments in early stage companies and was established under the Equity Capital Program by the Ministry of Competition, Sciences and Enterprise in the Province of British Columbia, Canada. This program is ideal for investors who want to be actively involved in the growth of small business throughout B.C. and offers companies the same benefits as a Venture Capital Corporation (VCC). For more information about this program, visit [www.equitycapital.gov.bc.ca](http://www.equitycapital.gov.bc.ca).

“I am pleased Kinexus has qualified for the EBC status,” said Mr. David Turner, Chief Executive Officer of Kinexus. “This allows B.C. investors who make an eligible investment in Kinexus to receive a 30% refundable tax credit”. Since its incorporation in July 1999, Kinexus has raised CAD \$3.6 million through private financing, and an additional \$2.9 million through grants, investment tax credits and revenues. Kinexus is currently seeking additional funds to permit the expansion of the company’s capabilities for disease and drug profiling systems by developing peptide antibody mimetics (PAM) for protein microarrays and drug and toxin profiling services.

Kinexus is poised to become a major proteomics and bioinformatics company with a focus on protein kinases and other cell signalling proteins for diagnostic and therapeutic applications. Kinexus currently offers 9 unique signal transduction protein profiling services for the detection of over 350 known cell signalling proteins, with revolutionary technology in late stage development. Over 300 major research centers, institutes and laboratories world-wide, including 60 corporate pharmaceutical and biotech clients, have used the Kinetworks™ Services as a cost-effective solution to identify proteins that may be relevant in different model systems and disease states. All of the Kinetworks™ screens are reliable, robust, highly sensitive, and utilize proprietary technologies designed to mitigate the risk while maximizing prospects in discovery-based research. The application of these methods in characterizing cell signalling networks provides Kinexus, its clients and associates with powerful knowledge for drug development, rational drug design, disease diagnosis, and eventually personalized therapies.

**For further information, please contact Kinexus Bioinformatics Corporation  
toll free at 1-866-KINEXUS or visit our website at [www.kinexus.ca](http://www.kinexus.ca)**

**PRESS RELEASE - 2003 SEPTEMBER 19**